Clinical trial · Interventional
Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients
NCT01359501CI-TRIAL-00008321unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a two-year double blind, placebo-controlled, and randomized clinical trial, which is aimed to evaluate the effects of Chinese medical treatment on leucopenia after chemotherapy in breast cancer patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Leucopenia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chinese medical treatment-LCH1 | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chinese medical treatment
- interventionNames
- Drug: Chinese medical treatment-LCH1
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- WBC Count
- timeFrame
- 21-31 weeks, which depands on the patients' chemotherapy protocol.
- description
- All the patients will be stratified according to her chemotherapy protocol : "FEC\*6", "FEC\*4+Taxotere\*4", and "FEC\*3+Taxotere\*3". The WBC will be checked before receiving each cycle of chemotherapy and at the follow up 3 weeks after the completion of chemotherapy. If the participator receives the protocol "FEC\*6", her WBC will be checked every 3 weeks for 7 times. It will takes 21 weeks to get the values of WBC at 7 different time point. And it will takes 31 weeks and 24 weeks for participators receive the protocol "FEC\*4+Taxotere\*4" and "FEC\*3+Taxotere\*3", respectively.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed breast cancer patient (age ≧18, Stage I, II, IIIa) * Receive chemotherapy after operation Exclusion Criteria: * Before receiving operation and chemotherapy, the patient already have other chronic diseases. * Already have hematological malignancy and other lethal disease. * Pregnant. * Have severe psychological diseases.
References
Publications (0)
Data not yet available
No reference posted for this study.